

Message

---

**From:** Buist, Jennifer M [Jennifer.Buist@mallinckrodt.com]  
**Sent:** 1/8/2016 8:01:22 PM  
**To:** jeffrey.k.meyer@usdoj.gov  
**CC:** Harper, Karen [Karen.Harper@mallinckrodt.com]; Tetzlaff, Gail S [Gail.Tetzlaff@mallinckrodt.com]; Spaulding, Eileen L. [Eileen.Spaulding@mallinckrodt.com]  
**Subject:** Mallinckrodt Suspicious Orders

Dear Mr. Meyer,

Attached are orders Mallinckrodt has received within the last business day that we are reporting to the Drug Enforcement Administration as suspicious orders pursuant to 21 CFR 1301.74(b). These orders are on hold and will not be shipped unless, and until, Mallinckrodt's Controlled Substances Compliance Group completes its independent analysis of these suspicious orders and determines that the orders are not likely to be diverted into other than legitimate medical, scientific and industrial channels.

If you have any questions or concerns regarding this report, please contact Don Lohman at 314-654-3927.

Best regards,

Jen Buist | Sr. Data Analyst  
Controlled Substances Compliance  
**Mallinckrodt Pharmaceuticals**  
675 McDonnell Blvd | Hazelwood, MO 63042 | US  
T: 314.654.5625  
[jennifer.buist@mallinckrodt.com](mailto:jennifer.buist@mallinckrodt.com) | [www.mallinckrodt.com](http://www.mallinckrodt.com)

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.